Posted on 6/14/18
Immunomedics: Short-Term Risk, Long-Term Opportunity
Immunomedics (NASDAQ:IMMU) is a clinical-stage biotech pharmaceutical company specializing in cancer therapies. A market cap near $4.2 billion shows a tremendous amount of optimism about the . . .
Posted on 6/14/18
Recent Purchase: Johnson & Johnson
With Johnson & Johnson (JNJ) recently hitting 52-week lows and falling to the 3% yield threshold, there has been a lot of buzz around the stock . . .
Posted on 6/14/18
Synergy Pharmaceuticals Announces Amendment to CRG Debt Agreement
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has . . .
Posted on 6/14/18
Cardinal Health and Clayton, Dubilier & Rice Announce Partnership
Cardinal Health, Inc. (NYSE: CAH) and Clayton, Dubilier & Rice announced today that CD&R-managed funds will jointly invest with Cardinal Health in naviHealth, the largest manager . . .
Posted on 6/14/18
Healthcare Informatics Ranks SCIO Health Analytics in List of Top 100 Health IT Software Companies
SCIO Health Analytics announced today that for the second consecutive year it has earned placement in the distinguished Healthcare Informatics 100 list of top U.S. healthcare . . .
Posted on 6/13/18
Johnson & Johnson: Recent Price Drop Offers Opportunity
I have written about Johnson & Johnson (JNJ) several times in the past, but since the last article was around 8 months ago, I think an . . .
Posted on 6/13/18
Immunomedics Announces Pricing of Public Offering of Common Stock
MORRIS PLAINS, N.J., June 13, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the . . .
Posted on 6/13/18
Johnson & Johnson Presents at Goldman Sachs 39th Annual Global Healthcare Conference Call (Transcript)
Thank you everyone for joining us. I'm really pleased to have members of JNJ Research Team our final team. So a little bit different this time, . . .
Posted on 6/13/18
Can This Pharma's $14 Billion Bet Succeed?
A couple of years back, Pfizer Inc. (NYSE:PFE) took a lot of heat in order to pull off a massive $14 billion acquisition that added Xtandi . . .
Posted on 6/12/18
EpiVax Oncology Completes a $1.2M Bridge Financing
EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY . . .
Posted on 6/12/18
MeiraGTx Closes IPO
LONDON and NEW YORK, June 12, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the closing . . .
Posted on 6/12/18
Pharmapacks Raises $32.5 Million
Pharmapacks, a leading e-commerce company with a proprietary technology platform that empowers brands to reach millions of consumers with a complete and cost-effective logistics, fulfillment, marketing . . .
Posted on 6/12/18
Hu-manity.co And Orb Health Partner
PRINCETON, N.J.--(BUSINESS WIRE)--Hu-manity.co, a company designed to create decentralized human rights using proprietary technology and legal innovations on blockchains, has partnered with Orb Health, a leading . . .
Posted on 6/12/18
Cigna-Express Scripts: Analysis Of Each Stock And Of The Deal
Background: The top-down case for a fresh look at healthcare middlemenA theme I've had since February has been to look for anti-momentum stocks. Simple translation: depressed . . .
Posted on 6/12/18
Better Buy: Verizon Communications Inc. vs. Johnson & Johnson
It can be hard to evaluate companies in different industries, but investors who seek out diversified portfolios often face the challenge of choosing from high-quality stocks . . .
Posted on 6/12/18
Regeneron Pharmaceuticals (REGN) Investor Presentation - Slideshow
The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with this event. 128READ FULL ARTICLE HERE
Posted on 6/11/18
Kadmon Announces Proposed Public Offering of Common Stock
NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) today announced its intention to offer and sell shares of its common stock in a public offering pursuant to an . . .
Posted on 6/11/18
Immunomedics Announces Proposed Public Offering of Common Stock
MORRIS PLAINS, N.J., June 11, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that . . .
Posted on 6/11/18
NewYork-Presbyterian Medical Group Queens and Weill Cornell Medicine Welcome New Physicians
NewYork-Presbyterian Medical Group Queens and Weill Cornell Medicine are pleased to welcome the following new physicians to their expanding network of care:Xuming Dai, MD, Ashlesha K. . . .
Posted on 6/11/18
Alexion and Complement Pharma Announce Partnership
NEW HAVEN, Conn., & AMSTERDAM--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Complement Pharma today announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative . . .
Posted on 6/11/18
HC2 Sells BeneVir Biopharm To Janssen Biotech For $1.04 Billion
HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company, announced today that it has completed the sale of BeneVir Biopharm, Inc.,
Posted on 6/11/18
Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) announced today that the U.S. District Court for the District of Columbia (the Court) has issued a decision requiring . . .
Posted on 6/10/18
Johnson & Johnson: High-Quality Value Hiding In Plain Sight
Johnson & Johnson (JNJ) beat on both its top and bottom lines during its most recent quarter, but shares remain stagnant:Shares are still in "correction mode" . . .
Posted on 6/10/18
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 7, 2018 it approved non-statutory stock options to purchase an aggregate of 134,450 shares of its . . .
Posted on 6/10/18
PAVmed to Receive $10.4 Million in Gross Proceeds from Oversubscribed Rights Offering
NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multiproduct medical device company, today announced its previously announced equity subscription rights offering (the “Rights Offering”) . . .

